Telix withdraws Europe marketing application, AGL to close power station early and BHP prioritises Peru exploration
Telix Pharmaceuticals (ASX: TLX) has announced it has withdrawn its application to market the company’s lead prostate cancer imaging product, Illuccix, in Europe.